Haleon plc Reports Share Transaction
Ticker: HLNCF · Form: 6-K · Filed: Aug 26, 2025 · CIK: 1900304
Sentiment: neutral
Topics: share-transaction, 6-K
TL;DR
Haleon bought back some of its own stock on 8/26/25. Details in Exhibit 99.1.
AI Summary
Haleon plc announced on August 26, 2025, that it conducted a transaction involving its own shares. The filing, a Form 6-K, details this transaction as part of its reporting for August 2025. The specific details of the share transaction, including the number of shares and the price, are not provided in this summary document but are referenced as Exhibit 99.1.
Why It Matters
This filing indicates corporate activity related to Haleon's own stock, which can impact share count and potentially signal management's view on the company's valuation.
Risk Assessment
Risk Level: low — The filing is a routine report of a transaction in own shares, not indicating significant new risks.
Key Players & Entities
- Haleon plc (company) — Registrant
- 26 August 2025 (date) — Date of transaction announcement
- 001-41411 (other) — Commission File Number
FAQ
What type of transaction did Haleon plc conduct on August 26, 2025?
Haleon plc conducted a transaction in its own shares on August 26, 2025.
What is the filing type and reporting period for this document?
This is a Form 6-K, reporting for the month of August 2025.
Where can more details about the share transaction be found?
More details can be found in Exhibit 99.1, titled 'Transaction in Own Shares'.
What is Haleon plc's commission file number?
Haleon plc's commission file number is 001-41411.
Is Haleon plc required to file annual reports under Form 20-F or 40-F?
Haleon plc is required to file annual reports under Form 20-F.
Filing Stats: 572 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2025-08-26 07:18:07
Filing Documents
- a5087w.htm (6-K) — 33KB
- a5087w000.jpg (GRAPHIC) — 3KB
- 0001654954-25-009994.txt ( ) — 39KB
From the Filing
IN OWN SHARES a5087w UNITED STATES   SECURITIES AND EXCHANGE COMMISSION   Washington, D.C. 20549     FORM 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934   For the month of August 2025   Commission File Number: 001-41411   Haleon plc (Translation of registrant’s name into English)   Building 5, First Floor, The Heights, Weybridge, Surrey, KT13 0NY (Address of principal executive offices)     Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:     Form 20-F ☒   Form 40-F ☐       EXHIBIT INDEX   Exhibit Number Description 99.1 26 August 2025 - “Transaction in Own Shares”     99.1     Haleon plc:   Transaction in own shares   26 August 2025:   Haleon plc (the "Company" or "Haleon") today announces   the purchase of 1,369,903 ordinary shares of £0.01 each in the Company (the "Shares") for cancellation   under the second tranche of its share buyback programme announced on 31 July 2025.     London Stock Exchange CBOE (UK)/BXE CBOE (UK)/CXE Date of purchase: 22 August 2025 22 August 2025 22 August 2025 Number of Shares purchased: 1,369,903 - - Highest price paid per Share (p): 368.0000 - - Lowest price paid per Share (p): 364.2000 - - Volume weighted average price paid per Share (p): 366.7394 - -   Following the settlement of the above, the Company's registered share capital   is 8,969,326,205 ordinary shares of £0.01 each, of which 3,880,205 are held as treasury shares.   Therefore, the number of ordinary shares with voting rights is 8,965,446,000 and   this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.   In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:   http://www.rns-pdf.londonstockexchange.com/rns/5079W_1-2025-8-22.pdf   This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.   This announcement and individual trade breakdown will also be available on the Company's website at:   www.haleon.com/investors .   Enquiries     Investors Media   Jo Russell   +44 7787 392441 Zoë   Bird +44 7736 746167 Rakesh Patel      +44 7552 484646 Victoria Durman +44 7894 505730 Email:   investor-relations@haleon.com Email:   corporate.media@haleon.com   About Haleon Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as  Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu  and  Voltaren  - are built on trusted science, innovation and deep human understanding.   For more information, please visit   www.haleon.com .            SIGNATURE       Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.       HALEON PLC (Registrant)   Date: August 26, 2025 By: /s/ Amanda Mellor     Name: Amanda Mellor     Title: Company Secretary